Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 2:26:e5.
doi: 10.1017/erm.2024.8.

Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness

Maria Patrizia Mongiardi  1 , Roberto Pallini  2 , Quintino Giorgio D'Alessandris  3 , Andrea Levi  1 , Maria Laura Falchetti  1
Affiliations
Review

Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness

Maria Patrizia Mongiardi et al. Expert Rev Mol Med. .

Abstract

Glioblastoma IDH wild type (GBM) is a very aggressive brain tumour, characterised by an infiltrative growth pattern and by a prominent neoangiogenesis. Its prognosis is unfortunately dismal, and the median overall survival of GBM patients is short (15 months). Clinical management is based on bulk tumour removal and standard chemoradiation with the alkylating drug temozolomide, but the tumour invariably recurs leading to patient's death. Clinical options for GBM patients remained unaltered for almost two decades until the encouraging results obtained by the phase II REGOMA trial allowed the introduction of the multikinase inhibitor regorafenib as a preferred regimen in relapsed GBM treatment by the National Comprehensive Cancer Network (NCCN) 2020 Guideline. Regorafenib, a sorafenib derivative, targets kinases associated with angiogenesis (VEGFR 1-3), as well as oncogenesis (c-KIT, RET, FGFR) and stromal kinases (FGFR, PDGFR-b). It was already approved for metastatic colorectal cancers and hepatocellular carcinomas. The aim of the present review is to focus on both the molecular and clinical knowledge collected in these first three years of regorafenib use in GBM.

Keywords: glioblastoma IDH-wild type; glioma stem cells; multikinase inhibitor; regorafenib; therapy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Current therapeutic approach for GBM patients. First-line treatment for GBM patients is based on surgery and adjuvant chemoradiation with the alkylating agent temozolomide. At tumour relapse, second-line treatment is lomustine, the humanised monoclonal antibody bevacizumab, which targets vascular endothelial growth factor (approved limiting to US, Japan and China) and the recently approved regorafenib. Created with Biorender.com.
Figure 2.
Figure 2.
Molecular structure of regorafenib. Created with Biorender.com
Figure 3.
Figure 3.
Molecular targets of regorafenib. Regorafenib targets stromal (FGFR, PDGFR), angiogenic (VEGFRs, Tie-2) and oncogenic kinases (RET, KIT). Created with Biorender.com.
See this image and copyright information in PMC

References

    1. Louis DN et al. (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology 23, 1231–1251. - PMC - PubMed
    1. Brat DJ et al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for ‘Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV’. Acta Neuropathologica 136, 805–810. - PMC - PubMed
    1. Stichel D et al. (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica 136, 793–803. - PubMed
    1. Verhaak RG et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110. - PMC - PubMed
    1. Stupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 352, 987–996. - PubMed

MeSH terms